Li-xin Pan

Nanning, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Adjuvant immunotherapy for hepatocellular carcinoma: Precision selection of the optimal target population as the core strategy.

Adjuvant immunotherapy for hepatocellular carcinoma: Precision selection of the optimal target population as the core strategy.

Journal: Journal of hepatology

Published: February 02, 2026

Construction of TLS-related gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma.

Construction of TLS-related gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma.

Journal: Hepatology communications

Published: August 24, 2025

Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006).

Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006).

Journal: Liver cancer

Published: August 16, 2025

Sintilimab as adjuvant therapy for high-risk hepatocellular carcinoma after curative resection: a multicentric retrospective cohort study.

Sintilimab as adjuvant therapy for high-risk hepatocellular carcinoma after curative resection: a multicentric retrospective cohort study.

Journal: European journal of gastroenterology & hepatology

Published: July 01, 2025

Tertiary lymphoid structures in HCC: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy.

Tertiary lymphoid structures in HCC: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy.

Journal: Hepatology (Baltimore, Md.)

Published: March 07, 2025

Identification of a liver fibrosis and disease progression-related transcriptome signature in non-alcoholic fatty liver disease.

Identification of a liver fibrosis and disease progression-related transcriptome signature in non-alcoholic fatty liver disease.

Journal: The international journal of biochemistry & cell biology

Published: December 18, 2024

Treatment Duration of Adjuvant Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Patients at High Risk of Recurrence after Resection: A Prospective, Multicentric Cohort Study.

Treatment Duration of Adjuvant Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Patients at High Risk of Recurrence after Resection: A Prospective, Multicentric Cohort Study.

Journal: Liver cancer

Published: September 02, 2024

lncSNHG16 promotes hepatocellular carcinoma development by inhibiting autophagy.

lncSNHG16 promotes hepatocellular carcinoma development by inhibiting autophagy.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: August 02, 2024

Adjuvant Therapy for Hepatocellular Carcinoma After Curative Treatment: Several Unanswered Questions.

Adjuvant Therapy for Hepatocellular Carcinoma After Curative Treatment: Several Unanswered Questions.

Journal: Journal of clinical and translational hepatology

Published: January 19, 2024

Prognostic value of aspartate aminotransferase/alanine aminotransferase ratio in hepatocellular carcinoma after hepatectomy.

Prognostic value of aspartate aminotransferase/alanine aminotransferase ratio in hepatocellular carcinoma after hepatectomy.

Journal: BJS open

Published: July 12, 2023

Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial.

Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial.

Journal: Trials

Published: July 11, 2023

miR-17-5p slows progression of hepatocellular carcinoma by downregulating TGFβR2.

miR-17-5p slows progression of hepatocellular carcinoma by downregulating TGFβR2.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: January 27, 2023

Showing 1-12 of 13

Last Updated: 09/26/2026